FDA rejects ivonescimab for lung cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA rejects ivonescimab for lung cancer

  • By

  • Mouj Hijazi

  • November 16, 2026

  • 2 min

Share

  • 1

    The FDA declined to approve ivonescimab plus platinum-containing chemotherapy for previously treated, locally advanced or metastatic NSCLC.

  • 2

    The FDA issued a Complete Response Letter, citing insufficient evidence of an overall survival benefit.

  • 3

    The agency concluded that progression-free survival benefit alone did not establish a favorable benefit-risk profile.

  • 4

    In the phase 3 HARMONi trial, the combination met both primary progression-free survival endpoints, but overall survival improvement was not statistically significant.

  • 5

    Ivonescimab remains investigational and unapproved in the United States, although it has marketing authorization in China.

Original Source(s)

Related Content